Clinical Trials Browser

Phase 2 × Liver Neoplasms × Nivolumab × Clear all

NCT03785210 2026-02-23

Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers

Phase 2 Terminated

22 enrolled 13 charts

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04912765 2025-09-23

Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Colorectal Neoplasms

NCT03572582 2023-07-20

IMMUTACE

Phase 2 Completed

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05039736 2023-05-12

A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy

Phase 2 Withdrawn

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05471674 2023-02-01

Neoadjuvant Anti-PD1 in HCC

Phase 2 Completed

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03380130 2020-11-04

NASIR-HCC

Phase 2 Completed

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Phase 2 Unknown

BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms